Nordea Investment Management
MYGN icon

Nordea Investment Management’s Myriad Genetics MYGN Stock Holding History

Nordea Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-341,483
Closed -$1.49M – 951
2026
Q1 		$1.49M Sell
341,483
-27,668
-7% -$144K ﹤0.01% 790
2025
Q4 		$2.26M Sell
369,151
-47,040
-11% -$341K ﹤0.01% 732
2025
Q3 		$2.97M Buy
416,191
+13,281
+3% +$78.9K ﹤0.01% 691
2025
Q2 		$2.15M Buy
402,910
+65,781
+20% +$389K ﹤0.01% 720
2025
Q1 		$2.95M Buy
337,129
+4,216
+1% +$50.6K ﹤0.01% 631
2024
Q4 		$4.55M Buy
332,913
+179,527
+117% +$3.31M ﹤0.01% 557
2024
Q3 		$4.1M Sell
153,386
-8,256
-5% -$223K ﹤0.01% 565
2024
Q2 		$3.9M Buy
161,642
+32,739
+25% +$718K ﹤0.01% 579
2024
Q1 		$2.77M Buy
128,903
+6,807
+6% +$146K ﹤0.01% 660
2023
Q4 		$2.34M Sell
122,096
-5,213
-4% -$90.2K ﹤0.01% 680
2023
Q3 		$2.02M Sell
127,309
-4,534
-3% -$86.3K ﹤0.01% 688
2023
Q2 		$3.09M Sell
131,843
-47,422
-26% -$1.03M ﹤0.01% 617
2023
Q1 		$4.18M Sell
179,265
-2,768
-2% -$56.2K 0.01% 557
2022
Q4 		$2.56M Sell
182,033
-19,096
-9% -$356K ﹤0.01% 628
2022
Q3 		$3.98M Sell
201,129
-1,069
-0.5% -$24.5K 0.01% 572
2022
Q2 		$3.67M Sell
202,198
-21,773
-10% -$452K 0.01% 606
2022
Q1 		$5.78M Buy
223,971
+3,049
+1% +$78K 0.01% 556
2021
Q4 		$6.26M Sell
220,922
-1,669
-0.7% -$48.4K 0.01% 538
2021
Q3 		$7.36M Buy
222,591
+3,149
+1% +$105K 0.01% 500
2021
Q2 		$6.71M Buy
219,442
+83,448
+61% +$2.41M 0.01% 540
2021
Q1 		$4.07M Sell
135,994
-2,325
-2% -$66K 0.01% 615
2020
Q4 		$2.73M Sell
138,319
-3,684
-3% -$59.5K ﹤0.01% 655
2020
Q3 		$1.85M Sell
142,003
-142,003
-50% -$1.8M ﹤0.01% 663
2020
Q2 		$3.09M Buy
284,006
+144,820
+104% +$2.06M ﹤0.01% 668
2020
Q1 		$2.05M Buy
139,186
+4,095
+3% +$86.5K ﹤0.01% 646
2019
Q4 		$3.63M Buy
135,091
+4,102
+3% +$113K 0.01% 635
2019
Q3 		$3.75M Buy
130,989
+919
+0.7% +$26.8K 0.01% 621
2019
Q2 		$3.61M Sell
130,070
-1,199
-0.9% -$33.9K 0.01% 627
2019
Q1 		$4.36M Buy
131,269
+24,512
+23% +$746K 0.01% 655
2018
Q4 		$3.1M Buy
106,757
+5,274
+5% +$190K 0.01% 735
2018
Q3 		$4.67M Buy
101,483
+19,417
+24% +$863K 0.01% 605
2018
Q2 		$3.07M Sell
82,066
-4,811
-6% -$162K 0.01% 644
2018
Q1 		$2.57M Buy
86,877
+15,599
+22% +$528K 0.01% 697
2017
Q4 		$2.45M Sell
71,278
-6,900
-9% -$233K 0.01% 615
2017
Q3 		$2.83M Buy
78,178
+6,026
+8% +$172K 0.01% 516
2017
Q2 		$1.86M Sell
72,152
-12,045
-14% -$256K ﹤0.01% 671
2017
Q1 		$1.62M Buy
84,197
+12,903
+18% +$229K ﹤0.01% 633
2016
Q4 		$1.19M Buy
71,294
+15,249
+27% +$276K ﹤0.01% 690
2016
Q3 		$1.15M Buy
56,045
+36,203
+182% +$918K ﹤0.01% 639
2016
Q2 		$607K Buy
+19,842
New +$689K ﹤0.01% 703

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nordea Investment Management's MYGN Position: Q2 2026 in Review

Nordea Investment Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 341,483 shares — an estimated $1.49M sold.

Nordea Investment Management first reported a position in MYGN in Q2 2016 and held it in 40 quarters. The position peaked at $7.36M in Q3 2021. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Nordea Investment Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Nordea Investment Management sold 341,483 Myriad Genetics shares in Q2 2026, an estimated $1.49M.
  • Nordea Investment Management first reported a position in Myriad Genetics in Q2 2016 and held it in 40 quarters.
  • Nordea Investment Management's Myriad Genetics position peaked at $7.36M in Q3 2021.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Nordea Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.